Congenital Disorders of Glycosylation (CDG Syndrome)

Congenital Disorders of Glycosylation (CDG) are a large group of rare, inherited conditions where the body has trouble attaching sugar chains (called glycans) to proteins and fats. This step—glycosylation—is essential for almost every cell and organ. When glycosylation is faulty, organs like the brain, liver, heart, muscles, immune system, and blood-clotting system can be affected. Most CDG start in infancy and cause mixed symptoms such as weak muscle tone, feeding problems, developmental delay, seizures, abnormal blood tests, hormone problems, and liver or heart issues. Diagnosis relies on clinical evaluation plus special laboratory tests that look at glycan patterns (for example, transferrin isoforms) and genetic testing. The names now use the gene name + “-CDG” (e.g., PMM2-CDG). Children’s Hospital of Philadelphia+3PMC+3NCBI+3

What “CDG type” means today

Historically, doctors used Type I and Type II for N-glycosylation problems:

• Type I (CDG-I): defects in building the sugar chain and transferring it onto the protein.

• Type II (CDG-II): defects in trimming and processing the sugar chain after transfer.

This Type I/II split is still useful for some tests, but modern classification is broader and groups CDG into four major families: disorders of protein N-glycosylation, protein O-glycosylation, glycosphingolipid/GPI-anchor glycosylation, and multiple-pathway (combined) disorders. Many centers now also list well-known gene-named types (e.g., PMM2-CDG, MPI-CDG, PGM1-CDG, SLC39A8-CDG, TMEM165-CDG, SLC35C1-CDG). Children’s Hospital of Philadelphia+5Children’s Hospital of Philadelphia+5PMC+5

Congenital Disorders of Glycosylation—often shortened to CDG—are a big group of rare genetic diseases that begin at birth. In CDG, the body has trouble making and attaching small sugar chains (called glycans) to proteins and fats. This sugar-attachment process is named glycosylation. When glycosylation does not work well, many proteins cannot fold, travel, or function properly. Because proteins are used in almost every part of the body, CDG can affect the brain, nerves, muscles, liver, heart, hormone system, blood, eyes, intestines, and more. Symptoms are very different from person to person. Some children have mild problems and grow into adulthood; others have severe illness in infancy. Most CDG types are inherited, usually in an autosomal recessive way (both parents carry one changed gene). A few types can be X-linked or dominant. There is no single cure, but some types have targeted treatments (for example, sugar supplements) and many symptoms can be managed with supportive care. Insights+3GARD Information Center+3Rare Diseases+3

---

Other names

• Carbohydrate-deficient glycoprotein syndrome (CDGS): an older name used before the family of conditions was fully understood.

• Jaeken syndrome: an older name often used for PMM2-CDG, the most common type.

• Type I / Type II CDG: earlier lab-based labels that referred to specific transferrin patterns; today we more often use gene-based names (for example, PMM2-CDG, MPI-CDG, PGM1-CDG).

• N-linked, O-linked, GPI-anchor, or multiple pathway CDG: broad class names based on which glycosylation pathway is affected. Insights+1

---

Types

Doctors group CDG by which glycosylation pathway is affected and, more precisely, by the gene that is changed. Key classes are:

1. Disorders of protein N-glycosylation (the most common group; includes PMM2-CDG, ALG-gene CDGs, DPAGT1-CDG, SRD5A3-CDG, STT3A-CDG, etc.). Rare Diseases+4NCBI+4Orpha.net+4

2. Disorders of protein O-glycosylation (problems adding O-linked glycans to proteins). CDG Hub

3. Disorders of glycosphingolipid and GPI-anchor glycosylation (affecting special lipids or anchors that hold proteins on cell surfaces). PMC

4. Combined or multiple glycosylation pathway disorders (more than one pathway is affected). PMC

Within each class, gene-named subtypes are recognized (for example, PMM2-CDG is the most common; PGM1-CDG often causes low blood sugar; ALG1-CDG may cause severe early seizures; SRD5A3-CDG often affects vision). MedlinePlus+3NCBI+3Rare Diseases Network+3

---

Causes

“Cause” here means which gene change interrupts glycosylation. Most are autosomal recessive. Below are common, illustrative causes with what each gene normally helps do:

1. PMM2-CDG: changes in PMM2 lower phosphomannomutase activity, blocking early N-glycan steps; this is the most common CDG. NCBI+1

2. MPI-CDG: MPI defects reduce mannose-6-phosphate isomerase; some benefit from oral mannose therapy. NCBI

3. PGM1-CDG: PGM1 changes affect glucose-to-glucose-1-phosphate conversion; can cause hypoglycemia and muscle problems. Rare Diseases Network

4. DPAGT1-CDG: DPAGT1 defects impair building the lipid-linked oligosaccharide, an early N-glycan step. NCBI

5. RFT1-CDG: RFT1 changes disrupt flipping of the growing sugar chain across the ER membrane. NCBI

6. DPM1/2/3-CDG: defects in dolichol-phosphate-mannose synthesis used in N-glycan and GPI-anchor pathways. NCBI

7. DOLK-CDG: DOLK changes reduce dolichol kinase activity needed for making lipid-linked oligosaccharides. NCBI

8. ALG1-CDG: ALG1 loss impairs early mannose addition in N-glycan assembly, often with severe seizures. GARD Information Center

9. ALG3-CDG: ALG3 defects disturb mannose addition in N-glycan core building. NCBI

10. ALG6-CDG: ALG6 defects impair glucosylation of the N-glycan precursor. NCBI

11. ALG8-CDG: ALG8 changes further disturb glucosyl steps in the ER. NCBI

12. ALG12-CDG: ALG12 mutations affect later mannose additions. NCBI

13. ALG13-CDG (often X-linked): defects in a glycosyltransferase; frequently presents with epilepsy. NCBI

14. SRD5A3-CDG: SRD5A3 is needed to make dolichol; loss affects many glycosylation steps and often the eyes/brain. MedlinePlus

15. STT3A-CDG: STT3A changes impair the oligosaccharyltransferase complex that attaches glycans to proteins. Rare Diseases

16. SLC35A2-CDG: a UDP-galactose transporter problem; some reports of galactose supplementation benefit. PMC

17. SLC35C1-CDG (formerly LAD-II): GDP-fucose transporter defect; fucose therapy may help in some cases. PMC

18. TMEM165-CDG: a Golgi ion homeostasis protein; changes cause multisystem disease with skeletal findings. PMC

19. PGM3-CDG: affects UDP-GlcNAc supply; often prominent immune problems. PMC

20. GPI-anchor pathway CDGs (for example, PIGA, PIGT, PIGM): defects in building anchors that attach proteins to the cell surface. PMC

(Note: The field evolves quickly; the number of recognized CDG genes keeps rising as new types are discovered.) Rare Diseases

---

Common symptoms and signs

1. Low muscle tone (hypotonia): the baby feels “floppy,” has a weak suck, and delays lifting the head. This happens because nerve and muscle proteins do not work well without proper glycans. GARD Information Center

2. Developmental delay: sitting, walking, and talking can be slow. Learning problems may appear later. Severity varies widely. GARD Information Center+1

3. Poor growth and feeding difficulty: trouble gaining weight, vomiting, or reflux; sometimes “failure to thrive.” GARD Information Center

4. Ataxia (poor balance and coordination): the child appears unsteady, with clumsy movements. In PMM2-CDG this is very common. NCBI

5. Seizures: brief staring spells or convulsions due to abnormal brain electrical activity; seizure types vary by CDG subtype. GARD Information Center

6. Eye problems: strabismus (crossed eyes), nystagmus (shaking eyes), or vision loss in some types. Orpha.net+1

7. Abnormal fat distribution and inverted nipples: a typical look in some N-glycosylation disorders like PMM2-CDG. Orpha.net+1

8. Stroke-like episodes: sudden weakness or trouble speaking that mimics a stroke; sometimes seen in PMM2-CDG. Rare Diseases

9. Liver problems: enlarged liver or abnormal liver tests; some develop liver disease. MedlinePlus

10. Bleeding or clotting problems: easy bruising or, at times, blood clots due to clotting factor issues. MedlinePlus

11. Endocrine issues: low blood sugar (hypoglycemia), thyroid problems, or puberty/hormone irregularities (for example, PGM1-CDG commonly shows hypoglycemia). Rare Diseases Network

12. Heart involvement: cardiomyopathy or fluid around the heart in some types. MedlinePlus

13. Gastrointestinal symptoms: chronic diarrhea or constipation as the gut lining and enzymes are affected. GARD Information Center

14. Neuropathy: numbness, pain, or weakness from nerve damage in selected subtypes and at older ages. NCBI

15. Frequent infections: some CDGs include immune system weakness, leading to repeated infections. PMC

---

Diagnostic tests

A) Physical examination

1. General growth and nutrition check: the clinician measures weight, length/height, and head size, and looks for feeding problems and poor growth. In CDG, many children are small for age or gain slowly. GARD Information Center

2. Neurologic exam for tone and reflexes: the doctor checks low tone, reflex strength, and coordination, which can show a brain or nerve problem due to glycosylation defects. NCBI

3. Eye alignment and movement exam: looking for strabismus or nystagmus that are common in several CDG types. Orpha.net

4. Skin and fat pattern inspection: searching for inverted nipples and unusual fat pads (a clue to PMM2-CDG). Orpha.net

5. Liver and spleen palpation: feeling for an enlarged liver/spleen that can appear in multiple CDGs. MedlinePlus

B) Manual bedside tests

6. Gait and balance tasks (tandem walking, standing feet together): show ataxia and balance issues common in N-glycosylation disorders. NCBI

7. Finger-to-nose and heel-to-shin: simple coordination checks that reveal cerebellar problems seen in many patients. NCBI

8. Developmental screening tools (e.g., ages-and-stages style checklists): track delays across motor, language, and social skills. GARD Information Center

9. Cranial nerve bedside tests (eye tracking, face movements, swallowing): help localize neurologic dysfunction related to glycosylation defects. NCBI

10. Manual muscle testing (graded strength): identifies weakness from neuropathy or myopathy that can accompany CDG. NCBI

C) Laboratory and pathological tests

11. Transferrin glycoform analysis (isoelectric focusing or mass spectrometry): the classic screening test for N-glycosylation disorders; shows Type I or Type II patterns or normal results in non-N defects. Insights

12. Serum N-glycan or O-glycan profiling by mass spectrometry: detailed patterns help narrow the pathway and point to certain genes. PMC

13. Targeted enzyme assays (e.g., PMM2, MPI, PGM1): confirm reduced activity in suspected subtypes and guide therapy (such as mannose for MPI-CDG or dietary strategies for PGM1-CDG). NCBI+1

14. Molecular genetic testing (CDG gene panel, exome/genome): today’s gold standard to pinpoint the exact CDG gene and inheritance. PMC

15. Coagulation tests (PT, aPTT, fibrinogen, antithrombin): look for bleeding or clotting risks common in several types. MedlinePlus

16. Liver function tests and metabolic screen (AST/ALT, albumin, glucose, thyroid studies): check organ involvement and common endocrine problems like hypoglycemia. GARD Information Center+1

D) Electrodiagnostic tests

17. Electroencephalogram (EEG): records brain waves to detect seizure activity and help choose anti-seizure treatment in CDG with epilepsy. GARD Information Center

18. Nerve conduction studies / EMG: measure nerve and muscle signals to confirm neuropathy or myopathy sometimes present in older children and adults with CDG. NCBI

E) Imaging tests

19. Brain MRI (with possible MR spectroscopy): may show cerebellar atrophy, white-matter changes, or other findings that support the diagnosis and help track progression. NCBI

20. Organ imaging (echocardiogram for heart, abdominal ultrasound for liver/spleen): checks for cardiomyopathy, pericardial effusion, or liver disease seen in select subtypes. MedlinePlus

Non-Pharmacological Treatments (therapies & others)

For each item: what it is, purpose, and simple mechanism.

1. Nutrition therapy and feeding support
   To ensure enough calories and safe swallowing. If oral feeding is unsafe or insufficient, clinicians may use thickened feeds, nasogastric tubes, or a gastrostomy tube. Adequate energy reduces failure to thrive and supports brain and muscle development. NCBI

2. Reflux and aspiration prevention
   Upright positioning after feeds, smaller frequent meals, and swallowing therapy lower the risk of aspiration pneumonia and discomfort. This protects lungs and improves feeding endurance. NCBI

3. Physiotherapy (gross motor)
   Daily, structured movement to build strength, balance, and posture. It stimulates neuro-motor pathways and prevents contractures and deconditioning common in hypotonia. NCBI

4. Occupational therapy (fine motor & self-care)
   Trains hand use, sitting balance, dressing, and adaptive skills. It uses repetitive practice to strengthen functional neural circuits and independence. NCBI

5. Speech-language therapy (including feeding/oral-motor)
   Supports communication and safe swallowing by practicing muscle coordination and breath control, and by providing augmentative communication when needed. NCBI

6. Vision and hearing rehabilitation
   Early glasses, strabismus management, low-vision tools, and hearing aids/cochlear support help brain development by improving sensory input quality. NCBI

7. Seizure self-management education
   Family training on seizure first aid, triggers, and medication adherence lowers injury risk and improves control alongside medical treatment. NCBI

8. Hydration and sick-day plans (especially for stroke-like episodes in PMM2-CDG)
   During acute neurologic “stroke-like” episodes, prompt hydration and glucose stabilization are recommended while clinicians exclude clots/bleeding. This supports brain perfusion. PMC

9. Anticoagulation risk counseling
   Because clotting and bleeding factors can both be abnormal in CDG, families learn signs of thrombosis/bleeding and peri-procedure precautions to reduce complications. PMC

10. Endocrine monitoring and replacement plans
    Regular checks for thyroid, growth, and blood sugar with prompt treatment support growth, attention, and energy. NCBI

11. Bone health program
    Weight-bearing activity, sunlight, calcium/vitamin D intake, and fall prevention protect against low bone density sometimes seen in CDG. CDG Hub

12. Cardiac surveillance and rehabilitation
    Periodic echocardiograms and activity plans address cardiomyopathy/arrhythmia risks that occur in some types. Early detection improves safety. NCBI

13. Liver care pathway
    Scheduled labs/ultrasound, nutrition tailored for liver disease, and infection prevention reduce complications in liver-involved CDG (e.g., MPI-, TMEM199-, CCDC115-, ATP6AP1-CDG). Frontiers

14. Immunization and infection-prevention hygiene
    Up-to-date vaccines and hand hygiene reduce infections, critical in types with immune issues (e.g., SLC35C1-CDG, some GPI-anchor defects). NCBI

15. Genetic counseling for family planning
    Explains inheritance, recurrence risks, and prenatal options. It supports informed decisions and earlier diagnosis in future pregnancies. PMC

16. Clinical trial participation when eligible
    Some CDG now have active interventional trials (e.g., acetazolamide for PMM2-CDG ataxia; GLM101 delivering mannose-1-phosphate). Trials provide monitored access to emerging therapies. fcdgc.rarediseasesnetwork.org+2ClinicalTrials.gov+2

17. School and developmental supports
    Individual education plans and assistive technologies optimize learning and social participation. Evidence shows early supports improve long-term outcomes in complex neurodevelopmental disorders. NCBI

18. Psychological support for family and patient
    Counseling reduces caregiver stress and supports adherence, which in turn improves medical outcomes. NCBI

19. Transition-of-care planning (adolescence → adulthood)
    Structured handover to adult services maintains continuity for epilepsy, endocrine, liver, and cardiology care. NCBI

20. Emergency care plan
    A written plan for seizures, stroke-like events, and bleeding/clotting risk speeds correct treatment in the ER. PMC

---

Drug Treatments

Note: Doses and timing are examples from published reports/guidelines; actual prescribing must be individualized by the treating specialists.

Disease-targeted (nutrient) therapies for selected CDG

1. D-Mannose for MPI-CDG
   Class/Purpose: Monosaccharide to bypass MPI block and restore glycosylation.
   Typical dose in reports: ~0.1–0.17 g/kg per dose, six times daily (≈0.6–1 g/kg/day total), with monitoring.
   Time/Mechanism: Mannose enters the salvage pathway to raise mannose-6-phosphate and normalize glycoprotein assembly; improvements reported in weeks to months; long-term benefit documented.
   Key precautions: Monitor liver tests, glucose, and transferrin profile; GI side effects possible. ScienceDirect+1

2. D-Galactose for PGM1-CDG
   Class/Purpose: Monosaccharide to improve N- and O-glycosylation and energy stores.
   Typical dose in reports: 0.5–1 g/kg/day (max ~50 g/day); pilot escalation up to 1.5 g/kg/day showed safety/benefit.
   Mechanism: Boosts UDP-galactose pools and glycan maturation; biochemical and clinical gains (e.g., transferrin normalization) documented.
   Adverse effects: GI upset; monitor glucose and galactosemia-related labs. ScienceDirect+2PMC+2

3. Manganese (MnSO₄) for SLC39A8-CDG
   Class/Purpose: Essential metal supplementation to correct manganese transporter deficiency.
   Typical dose in reports: Up to 15–20 mg Mn/kg/day (as manganese sulfate) with careful monitoring; dramatic biochemical and clinical responses reported.
   Mechanism: Restores Mn-dependent enzymes (e.g., β-1,4-galactosyltransferase); improves hearing, motor skills, and glycosylation profiles.
   Safety: Risk of manganese neurotoxicity—requires strict dosing and lab/clinical monitoring. NCBI+2ScienceDirect+2

4. D-Galactose ± Manganese for TMEM165-CDG (selected cases)
   Purpose/Mechanism: Restores Golgi Mn²⁺ homeostasis and galactosylation; combined therapy showed biochemical and clinical benefit in recent case evidence. PubMed+1

5. L-Fucose for SLC35C1-CDG (LAD-II)
   Class/Purpose: Monosaccharide to rescue fucosylation and improve immune function and development.
   Typical dose in reports: ~0.04–1.5 g/kg/day (up to ~16 g/day), divided; responses vary.
   Mechanism: Enters GDP-fucose salvage pathway, improving neutrophil selectin ligands and glycoprotein fucosylation; infections and labs can improve.
   Considerations: Not all patients respond; close specialist monitoring. CDG Hub+1

6. Sodium butyrate for PIGM-CDG (selected)
   Class/Purpose: Histone-deacetylase inhibitor to upregulate PIGM gene expression.
   Use: Case-level evidence shows improved seizures and glycan expression; highly specialized, off-label. World CDG Organization+1

7. Uridine for CAD-CDG (selected)
   Class/Purpose: Nucleotide supplement to bypass pyrimidine synthesis defects; reported improvements in small cohorts. PMC

Symptom-directed medicines commonly used in CDG (type-specific risks apply)

8. Levetiracetam (anti-seizure)
   Purpose/Mechanism: Broad-spectrum AED; modulates synaptic vesicle protein SV2A to reduce seizures. Often first-line for safety profile. Specialist dosing. NCBI

9. Valproate or alternative AEDs
   Purpose: Seizure control; mechanism via GABAergic enhancement and sodium channel effects.
   Caution: Valproate can affect liver; many CDG have liver disease—hepatology input is essential. NCBI

10. Topiramate / Clobazam / Others
    Purpose: Adjunctive seizure control tailored to seizure type and comorbidities. NCBI

11. Acetazolamide (for PMM2-CDG ataxia/SLE in research & off-label use)
    Purpose/Mechanism: Carbonic anhydrase inhibitor; lowers neuronal pH excitability, sometimes stabilizes cerebellar function; open-label data and an ongoing randomized trial exist.
    Use: Specialist-guided trials; benefit signals reported in speech and motor symptoms in some cohorts. ScienceDirect+2PubMed+2

12. Baclofen (spasticity)
    GABA-B agonist to reduce muscle spasm and improve mobility; dosing individualized. NCBI

13. Gabapentin or pregabalin (neuropathic pain/tone)
    Modulates calcium channels to reduce neuropathic discomfort and irritability. NCBI

14. Propranolol or primidone (tremor, selected)
    Adrenergic or GABAergic modulation to reduce disabling tremor where present. NCBI

15. Anticoagulants for proven thrombosis / high risk periods
    Warfarin or DOACs per hematology when indicated; careful balance because CDG can have both bleeding and clotting abnormalities; peri-procedural plans follow standard best-practice guidelines. American Society of Hematology+1

16. Desmopressin / factor concentrates (bleeding episodes)
    Used by hematology for specific deficiencies; goal is to replace or enhance missing clotting activity. NCBI

17. Levothyroxine (hypothyroidism when present)
    Replaces low thyroid hormone to improve growth, energy, and cognition. NCBI

18. Growth hormone (documented deficiency only)
    Stimulates growth and body composition; requires endocrine assessment and monitoring. NCBI

19. Proton-pump inhibitors / H2 blockers (reflux)
    Reduce stomach acid to protect esophagus and improve feeding tolerance in severe GERD. NCBI

20. Vitamin K during bleeding risk / abnormal INR (per specialist)
    Supports clotting factor gamma-carboxylation in certain settings; used under hematology guidance. NCBI

In development: GLM101 (liposomal mannose-1-phosphate) is in clinical trials for PMM2-CDG; early data suggest potential benefit, but it is not yet approved. ScienceDirect+1

---

Dietary Molecular Supplements

1. D-Mannose for MPI-CDG (specialist-directed dosing and monitoring). Mechanism: raises mannose-6-phosphate to restore N-glycan assembly. PubMed

2. D-Galactose for PGM1-CDG (specialist dosing). Mechanism: increases UDP-galactose for glycan finishing. ScienceDirect

3. Manganese sulfate for SLC39A8-CDG (strict monitoring). Mechanism: restores Mn-dependent glycosyltransferases. NCBI

4. L-Fucose for SLC35C1-CDG in selected responders. Mechanism: fuels GDP-fucose salvage. CDG Hub

5. Sodium butyrate for PIGM-CDG (rare, case-based). Mechanism: epigenetic upregulation of PIGM. World CDG Organization

6. Uridine for CAD-CDG. Mechanism: bypasses de novo pyrimidine synthesis bottleneck. PMC

7. Calcium and Vitamin D (general bone health). Mechanism: supports bone mineralization in low density states. CDG Hub

8. Iron (if iron-deficient) to improve anemia and energy; guided by labs. Mechanism: restores red cell production. NCBI

9. Omega-3 fatty acids (general anti-inflammatory heart-brain support). Mechanism: membrane and neurotransmission support; adjunctive only. NCBI

10. Multivitamin with trace elements as advised (avoiding excess Mn unless indicated). Mechanism: covers micronutrient gaps that can worsen fatigue and immunity. NCBI

---

Immunity-Booster / Regenerative / Stem-Cell” Approaches

There are no approved “stem-cell drugs” for CDG. However, transplant procedures can be considered in very specific CDG subtypes with organ-dominant disease or severe immunodeficiency. These are major medical decisions done only in expert centers.

1. Hematopoietic stem cell transplantation (HSCT) in PGM3-CDG (selected cases)
   Used for severe immunodeficiency; reports show immune reconstitution in several patients, but risks are substantial and outcomes vary. Frontiers+1

2. Liver transplantation in ATP6AP1-CDG, CCDC115-CDG, and selected MPI-CDG
   Considered for end-stage liver disease; can normalize hepatic glycosylation profiles, though extrahepatic defects remain. Outcomes depend on indication and peri-transplant course. PMC+2MDPI+2

3. Cardiac transplantation in DOLK-CDG (selected)
   For refractory cardiomyopathy; rare and highly specialized. CDG Hub

4. Clinical-trial therapeutics (e.g., GLM101)
   Investigational replacement of a missing sugar phosphate inside cells (mannose-1-phosphate for PMM2-CDG). Not standard care yet. Glycomine

5. Targeted nutrient therapies (Mn, Gal, Fucose, Mannose)
   Although not “regenerative,” these causally correct specific metabolic blocks and can feel like disease-modifying in responders. PMC

6. Rehabilitation-driven neuroplasticity
   Intensive, repetitive therapy programs stimulate neural network remodeling; this is the safest “regenerative” strategy for function. NCBI

---

Surgeries

1. Gastrostomy tube placement
   Why: persistent unsafe swallowing or inadequate intake; improves nutrition, reduces aspiration, and eases medication delivery. NCBI

2. Strabismus surgery
   Why: persistent eye misalignment affecting vision development and comfort; improves alignment and binocular vision. NCBI

3. Orthopedic procedures (tendon lengthening, scoliosis correction)
   Why: contractures or spinal deformity limiting function or breathing; improves mobility and seating tolerance. CDG Hub

4. Liver transplantation
   Why: liver failure in specific CDG (e.g., ATP6AP1-, CCDC115-, selected MPI-CDG). Can normalize hepatic glycosylation and coagulation but is major surgery with risks. PMC

5. Cardiac transplantation
   Why: end-stage cardiomyopathy in rare types (e.g., DOLK-CDG). Reserved for cases refractory to medical therapy. CDG Hub

---

Preventions

1. Early, accurate diagnosis (specialized glycan testing + genetics) to open targeted nutrient options where available. Children’s Hospital of Philadelphia

2. Vaccinations on schedule to reduce infections, especially in immune-involved CDG. NCBI

3. Thrombosis/bleeding risk plans for surgery, immobilization, or long travel; hematology input reduces complications. PMC

4. Nutrition and reflux management to prevent aspiration, poor growth, and hospitalizations. NCBI

5. Regular endocrine and liver monitoring to catch treatable problems early. Frontiers

6. Physical activity and bone health to prevent fractures and deconditioning. CDG Hub

7. Vision/hearing screening to protect development. NCBI

8. Sick-day hydration plans to lower risk during fever, vomiting, or SLE-like episodes. PMC

9. Genetic counseling for family members to discuss carrier testing and future pregnancy options. PMC

10. Care coordination (neurology, hepatology, hematology, endocrinology, cardiology, rehab) to prevent gaps in care. NCBI

---

When to see doctors urgently

• New or worsening seizures, confusion, or “stroke-like” symptoms (sudden weakness, slurred speech, unsteady gait). PMC

• Signs of clot or bleeding: swollen/painful leg, chest pain/shortness of breath, severe nosebleeds, unusual bruising. PMC

• Feeding difficulty, choking, dehydration, or failure to gain weight. NCBI

• Persistent fever, repeated infections, especially in SLC35C1-CDG or GPI-anchor defects. NCBI

• Severe abdominal swelling, jaundice, very dark urine, or confusion (possible liver decompensation). Frontiers

• Any sudden vision or hearing change. NCBI

---

What to eat and what to avoid

What to eat  ideas:

1. Balanced calories and protein from whole foods to support growth and repair. NCBI

2. Frequent small meals if low energy or reflux limits large feeds. NCBI

3. Adequate fluids; use oral rehydration during illness per plan. PMC

4. Calcium-rich foods (dairy, fortified alternatives) plus vitamin D for bones. CDG Hub

5. Iron-containing foods (meats, legumes, leafy greens) if iron-deficient. NCBI

6. Omega-3 sources (fish, flax, chia) for general heart-brain support. NCBI

7. Fiber-rich fruits/vegetables for gut health and steady energy. NCBI

8. If prescribed nutrient therapy, take the exact sugar supplement (e.g., mannose/galactose/fucose) as directed; do not self-start. PubMed+2ScienceDirect+2

9. If manganese therapy is used, follow the specialist’s product and lab schedule only. NCBI

10. Work with a metabolic dietitian to tailor textures and calories to swallowing and growth needs. NCBI

What to avoid:

1. Self-prescribing supplements, especially manganese, because of toxicity risk. NCBI

2. Large single meals if reflux or aspiration risk is present. NCBI

3. High-bleeding-risk activities without precautions when clotting is abnormal. PMC

4. Abrupt stopping of anti-seizure drugs. NCBI

5. Unvetted “stem-cell” or “cure-all” products; not approved and potentially harmful. (Use clinical trials only.) PMC

6. Dehydration during illness; follow sick-day plan. PMC

7. Alcohol in adolescents/adults with liver involvement. Frontiers

8. Excess vitamin K supplements without hematology advice when on anticoagulants. American Society of Hematology

9. Herbal products that interact with AEDs/anticoagulants unless cleared by the team. American Society of Hematology

10. Delayed vaccinations in immune-involved CDG (coordinate exceptions with immunology). NCBI

---

Frequently Asked Questions

1. Is CDG one disease or many?
   Many. Over 130 genetic disorders affect glycosylation, so symptoms vary widely. PMC

2. What does “type” mean in CDG today?
   We now group CDG by the pathway affected (N-glycosylation, O-glycosylation, GPI/lipid glycosylation, or multiple pathways). Older N-glycan terms “Type I/Type II” are still seen in labs. PMC+1

3. Are there cures?
   A few types have targeted nutrient therapies (e.g., mannose for MPI-CDG, galactose for PGM1-CDG, manganese for SLC39A8-CDG, fucose for SLC35C1-CDG). Many others use comprehensive supportive care; research and trials are expanding. CDG Hub+3PubMed+3ScienceDirect+3

4. How are CDG diagnosed?
   By history/physical, specialized glycan testing (e.g., transferrin glycoforms), and genetic testing to name the exact gene (e.g., PMM2-CDG). Children’s Hospital of Philadelphia

5. Why do some CDG have sugar supplements as medicine?
   Because specific pathway “blocks” can be bypassed by supplying the right sugar or cofactor, allowing cells to build normal glycans. PMC

6. Is manganese safe?
   Only under strict specialist care for SLC39A8-CDG. Doses and monitoring are crucial to avoid neurotoxicity. Do not self-start. NCBI

7. What about acetazolamide for PMM2-CDG ataxia?
   Studies (including a randomized trial in progress) suggest benefit for some patients, but it is not yet approved as a disease-modifying therapy. ClinicalTrials+1

8. Can transplants help?
   Yes, in selected subtypes: liver transplant for severe liver disease (e.g., ATP6AP1-/CCDC115-CDG), HSCT for severe immunodeficiency (PGM3-CDG), and rare cardiac transplant (DOLK-CDG). PMC+2Frontiers+2

9. Why are clotting tests abnormal in CDG?
   Glycosylation helps build normal clotting factors, so both pro- and anticoagulant factors can be altered, causing a mix of bleeding and clot risks. PMC

10. What is the outlook?
    Outcomes vary by gene and severity. Early diagnosis, targeted therapies (when available), and coordinated care improve quality of life. PMC

11. Can diet alone treat CDG?
    Only specific, prescribed nutrient therapies help certain genes; general healthy diet supports growth but does not replace medical care. PubMed+1

12. Are there specialized clinics?
    Yes—multidisciplinary CDG clinics exist at major centers to coordinate testing and care. Mayo Clinic

13. Is the old name CDG-Ia still used?
    Sometimes in older papers. The recommended name is PMM2-CDG. NCBI

14. Can CDG cause stroke-like episodes?
    Yes, especially in PMM2-CDG; hydration and supportive care are advised during episodes as clinicians rule out true strokes/clots. PMC

15. Where can families find reliable information and research updates?
    GeneReviews, NORD, CDG Hub, and major academic centers publish updates and trial information. NCBI+2Rare Diseases+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.